FDA clears ImPACT’s computerized cognitive tests for concussion assessment

brain imaging

The FDA awarded ImPACT Applications de novo clearance for two new devices to evaluate a patient’s cognitive function following a suspected brain injury or concussion. While the devices are not meant to diagnose concussion or determine its treatment, they will be included in the medical evaluation for head injury.

The devices, dubbed the ImPACT (Immediate Post-Concussion Assessment and Cognitive Test) and ImPACT Pediatric, are computerized tests that assess cognitive skills that a head injury could affect, such as word memory, reaction time and word recognition, according to an FDA statement. Scores would be compared against an age-matched control database or to pre-injury baseline scores if available for the patient.

The ImPACT software is cleared for patients aged 12 to 59, and runs on a desktop or laptop computer. The pediatric version is cleared for those aged 5 to 11 and runs on a tablet.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The de novo review pathway is for novel, low- to moderate-risk devices that are first-of-its-kind. A new category was made under which the ImPACT devices and similar products will be regulated: Computerized Cognitive Assessment Aid for Concussion.

"ImPACT's FDA clearance is a huge step forward for the industry, for athletes and others who are at-risk of concussion-related injuries, as well as for licensed, trained medical professionals everywhere," said ImPACT Applications CEO Michael Wahlster, in an ImPACT statement.

The FDA go-ahead comes at a point where concussion awareness is rising. In March, the agency convened a public workshop to discuss potential biomarkers and their development and use in diagnosing traumatic brain injury.

- here's the FDA statement
- and here's the ImPACT statement

Related Articles:
FDA clarifies brain injury device regs as researchers race to better detect concussions
German radiosurgery player Brainlab invests $7M+ in Jan Medical for portable concussion
Philips partners with San Diego startup to develop hand-held concussion blood test

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.